The Yonglin Healthcare Foundation is to partner with BioNTech to develop mRNA-based cancer immunotherapies, said Terry Gou (郭台銘), founder of the foundation and manufacturing giant Hon Hai Precision Industry.
BioNTech is also planning to set up a clinical trial hub in Taiwan for mRNA-based cancer immunotherapies as part of its Asia-Pacific expansion, Gou wrote on Facebook on Friday.
The German biotech firm, which developed a widely used mRNA COVID-19 vaccine, said in a separate statement that it would collaborate with Yonglin after signing a memorandum of understanding with Retain Biotech Corp.
Photo: CNA
Retain Biotech, a Taiwan-based company sponsored by the foundation, is engaged in precision and genomic medicine and cell therapy for treating cancers, BioNTech said.
Gou said the German company has set up an office in Taiwan to perform an initial assessment of its cancer product candidate, BNT113, which is targeted at treating head and neck cancers.
Taiwan is expected to participate in BioNTech’s mRNA-based cancer immunotherapy development, he said.
BioNTech said that BNT113 is expected to be the first of several novel cancer immunotherapies that it anticipates assessing in the region.
Under the memorandum of understanding, Retain is expected to support the clinical evaluation of BNT113 in a randomized phase two clinical trial across the region, BioNTech said.
“BioNTech’s mRNA technology has not only saved the world from the COVID-19 pandemic, but also raised hopes that the technology will help medical circles take a leap in cancer treatment,” Gou said.
“That has been the intention of BioNTech founder and CEO Ugur Sahin, and it is the first time that he believes his wish to beat cancer could come true,” he said.
At Gou’s invitation, BioNTech executives in January visited the National Taiwan University Cancer Center to better understand Taiwan’s cancer treatment environment, its medical equipment and achievements in the biotech field.
While in Taiwan, the executives evaluated Taiwan’s needs in the hopes of creating a blueprint for treating cancer in the country, Gou said.
In July, he led a delegation to BioNTech’s headquarters in Germany to brief Sabin on Taiwan’s plans to work with the company on head and neck cancer, breast cancer and leukemia.
In the Facebook post, Gou praised the partnership, saying that Taiwan could not afford to be left behind in the battle against cancer.
BioNTech chief business officer Sean Marett said his company’s goal with the Retain agreement was to accelerate the development of innovative therapies to help address cancers, which have been highly prevalent in the region.
BioNTech said it planned to evaluate BNT113 in the broader Asia-Pacific region starting with clinical trials in Taiwan and in Australia’s Victoria state.
It will also assess the expansion of clinical activities to Japan, South Korea, Singapore and other economies in the region for cancer-related therapies, which already encompasses 18 product candidates in 23 ongoing clinical trials.
ANOTHER EMERGES: The CWA yesterday said this year’s fourth storm of the typhoon season had formed in the South China Sea, but was not expected to affect Taiwan Tropical Storm Gaemi has intensified slightly as it heads toward Taiwan, where it is expected to affect the country in the coming days, the Central Weather Administration (CWA) said yesterday. As of 8am yesterday, the 120km-radius storm was 800km southeast of Oluanpi (鵝鑾鼻), Taiwan’s southernmost tip, moving at 9kph northwest, the agency said. A sea warning for Gaemi could be issued tonight at the earliest, it said, adding that the storm is projected to be closest to Taiwan on Wednesday or Thursday. Gaemi’s potential effect on Taiwan remains unclear, as that would depend on its direction, radius and intensity, forecasters said. Former Weather Forecast
As COVID-19 cases in Japan have been increasing for 10 consecutive weeks, people should get vaccinated before visiting the nation, the Centers for Disease Control (CDC) said. The centers reported 773 hospitalizations and 124 deaths related to COVID-19 in Taiwan last week. CDC Epidemic Intelligence Center Director Guo Hung-wei (郭宏偉) on Tuesday said the number of weekly COVID-19 cases reported in Japan has been increasing since mid-May and surpassed 55,000 cases from July 8 to July 14. The average number of COVID-19 patients at Japan’s healthcare facilities that week was also 1.39 times that of the week before and KP.3 is the dominant
The Chinese Communist Party’s (CCP) working group for Taiwan-related policies is likely to be upgraded to a committee-level body, a report commissioned by the Mainland Affairs Council (MAC) said. As Chinese President Xi Jinping (習近平) is increasingly likely to upgrade the CCP’s Central Leading Group for Taiwan Affairs, Taiwanese authorities should prepare by researching Xi and the CCP, the report said. At the third plenary session of the 20th Central Committee of the CCP, which ended on Thursday last week, the party set a target of 2029 for the completion of some tasks, meaning that Xi is likely preparing to
US-CHINA TRADE DISPUTE: Despite Beijing’s offer of preferential treatment, the lure of China has dimmed as Taiwanese and international investors move out Japan and the US have become the favored destinations for Taiwanese graduates as China’s attraction has waned over the years, the Ministry of Labor said. According to the ministry’s latest income and employment advisory published this month, 3,215 Taiwanese university graduates from the class of 2020 went to Japan, surpassing for the first time the 2,881 graduates who went to China. A total of 2,300 graduates from the class of 2021 went to the US, compared with the 2,262 who went to China, the document showed. The trend continued for the class of 2023, of whom 1,460 went to Japan, 1,334 went to